Stock Analysis
Becton, Dickinson and Co.BDX
P/E 55.45×· 5Y range 32.19–81.94×· top 19% of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsBuy21 analystsP/E 55.4× sits at the 81st percentile of its 5.0978781656399725-year history.
Cash covers 4% of debt · Q3 2026.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Quality100
Risks
- Valuation45
- Profitability28
Mixed fundamentals at a demanding price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
What's happening with BDX
Profile
Strong earnings quality; profitability, growth, financial health and valuation lag behind.
How is each axis scored?
- Valuation45/100 · Weak
- P/E vs own history (81th pct)0/25
- FCF yield (5.2%)20/25
- P/S (2.6x)20/25
- EV/EBIT (35.6x)5/25
- Growth31/100 · Weak
- Revenue CAGR (1.9%)6/25
- Net income CAGR (-5.4%)0/25
- EPS CAGR 5Y (-7.6%)0/25
- Fwd implied growth (301.3%)25/25
- Profitability28/100 · Weak
- ROIC (3.7%)5/25
- ROE (3.9%)5/25
- Net margin (4.7%)6/25
- Operating margin (9.6%)12/25
- Financial Health39/100 · Weak
- Altman Z (2.00)18/25
- Current ratio (0.87)6/25
- Interest coverage (4.2x)10/25
- Net cash / debt (D/A 32%)5/25
- Quality100/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.72)25/25
- FCF conversion (290%)25/25
- Margin stability (σ 4.2%)25/25
- Moat57/100 · Moderate
- ROIC >12% years (0/9 yrs)0/25
- Median gross margin (45.4%)20/25
- FCF-positive years (9/9 yrs)25/25
- Worst-year net margin (worst 1.9%)12/25
Risk Flags
- ⚠P/E 55.4× at top 19% of 5-year history
About Becton, Dickinson and Co.
Becton Dickinson operates in four business units. Show more
Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Headquarters: FRANKLIN LAKES, NJ · Employees: 72,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
45D+P/E (TTM)55.4xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 32.2x–81.9x · 81st pct
P/FCF20.2xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.2%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.9%–8.1% · 91st pct
P/S (TTM)2.60xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.9x–7.2x · 15th pct
EV/EBIT35.6xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 19.3x–72.1x · 33rd pct
EV/Sales3.3xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E13.8xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.14xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-25.11A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.23%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio70.4%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
28EROIC3.7%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE3.9%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA1.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin4.7%D
Grade D: LowNet Income / Revenue
Operating Margin9.6%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin46.4%C
Grade C: AverageGross Profit / Revenue
FCF Margin13.6%C
Grade C: AverageFCF / Revenue
True FCF Margin12.3%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR1.9%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-5.4%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-7.6%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth301.3%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-10.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income27.5%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.3%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
39DAltman Z-Score2.00C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.87xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.34xD
Grade D: Low(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.2xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment5.9yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT8.4xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.69xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.04xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
100A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.72A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion289.8%A
Grade A: StrongFCF / Net Income
Margin Stability4.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.39xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Feld Michael Filed | Feld Michael | SellOpen market sale | -76 | |
Roque Vitor Filed | Roque Vitor | Tax withholding | -190 | |
Feld Michael Filed | Feld Michael | SellOpen market sale | -165 | |
Feld Michael Filed | Feld Michael | Tax withholding | -1049 | |
Polen Thomas E Jr Filed | Polen Thomas E Jr | Option exercise | -43278 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Polen Thomas E Jr Filed | Polen Thomas E Jr | SellOpen market sale | -4152 | |
Polen Thomas E Jr Filed | Polen Thomas E Jr | SellDisposition | -39126 | |
Polen Thomas E Jr Filed | Polen Thomas E Jr | Option exercise | +43.3K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
57CROIC >12% Years0/9 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)45.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years9/9 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor1.9%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.46
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.60
Cash & short-term investments per share (Finnhub)
Book Value / Share$89.64
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$16.81B
Total debt obligations (short + long term)
Cash & Equiv.$709.00M
Cash and short-term investments
Net Debt$16.10B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$24.42B
Shareholders' equity (book value)
Asset / Liability1.93xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$52.23B
Current Market Capitalization
Beta0.24B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Becton, Dickinson and Co. (BDX)
BDX is down 1.04% at the last close. Becton, Dickinson and Co. meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.00 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -2.72 suggests a low likelihood of earnings manipulation.
- Takes ~5.9 years to repay net debt from free cash flow.
- The stock currently yields 2.2% in dividends.
See how BDX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BDX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 12 | After-hours | 188.89 | +2.80% | 2.14 |
Frequently Asked Questions about BDX
What is the current Becton, Dickinson and Co. (BDX) stock price?
BDX is trading at $191.75 at the last market close, down 1.04% on the session. PreMarketPrice tracks BDX pre-market, intraday and after-hours prices.
Is BDX stock a buy right now?
PreMarketPrice's quantitative model rates Becton, Dickinson and Co.'s financial health at 39/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BDX stock overvalued?
Becton, Dickinson and Co. trades at a trailing P/E of 55.4 and our valuation score rates it 45/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Becton, Dickinson and Co. report earnings?
No confirmed earnings date is currently scheduled for BDX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Becton, Dickinson and Co. operate in?
Becton, Dickinson and Co. operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Becton, Dickinson and Co. do?
Becton Dickinson operates in four business units.
About Becton, Dickinson and Co. (BDX) Stock
Becton, Dickinson and Co. (BDX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Becton, Dickinson and Co. is trading at $191.75, down 1.04% on the day with a market capitalization of $52.2 billion. The financial health score for BDX is 39/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BDX stock.
BDX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Becton, Dickinson and Co. (BDX) across multiple dimensions:
- Pre-market price & movement: Real-time BDX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BDX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Becton, Dickinson and Co. across multiple reporting periods.
- Financial health score: A composite score of 39/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BDX.
- Sector peers: Compare BDX against 6 other healthcare stocks on key financial metrics.
Is BDX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Becton, Dickinson and Co. (BDX) as an investment. The financial health score of 39/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Becton, Dickinson and Co. (BDX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.